ReviewClinical, cosmetic and investigational dermatology2022

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.

Angelo Ruggiero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.